Management of Severe Aggression in Youth with Complex Trauma

Primary Pharmacological Approach

The American Academy of Child and Adolescent Psychiatry recommends risperidone as the first-line pharmacological treatment for severe aggression in youth with intellectual disability, with a 69% positive response rate versus 12% on placebo 2
Risperidone should be started at 0.5 mg/day and titrated slowly to 0.5-3.5 mg/day based on response and tolerability, with a moderate level of evidence supporting its efficacy 1, 2
Aripiprazole is an FDA-approved alternative for irritability in adolescents aged 13-17 years, though it may be considered for younger patients with severe aggression, with a moderate level of evidence supporting its efficacy 1, 2

When using atypical antipsychotics, monitoring for metabolic syndrome risk, movement disorders, and prolactin levels is crucial, with a high level of evidence supporting the importance of regular monitoring 1, 2
Metabolic syndrome risk should be monitored at baseline and every 3 months, with a moderate level of evidence supporting the efficacy of regular monitoring 1

Divalproex sodium is a preferred adjunctive agent for aggressive outbursts with emotional dysregulation, with a 53% response rate and a moderate level of evidence supporting its efficacy 1, 2
Lithium carbonate is FDA-approved for adolescents ≥12 years and can be used for conduct disorder with emotional dysregulation, with a moderate level of evidence supporting its efficacy 1, 2

The American Academy of Child and Adolescent Psychiatry recommends combining medication with trauma-focused cognitive behavioral therapy (TF-CBT) for the treatment of severe aggression in youth with complex trauma, with a high level of evidence supporting the efficacy of combined treatment 2, 3
TF-CBT should be modified for patients with borderline IQ, with a focus on adapting interventions to their cognitive abilities and involving family/caregivers extensively in treatment, with a moderate level of evidence supporting the efficacy of modified TF-CBT 4

The American Academy of Child and Adolescent Psychiatry recommends adapting all interventions to the patient's cognitive level, with concrete examples and visual supports, and involving family/caregivers extensively in both medication management and therapy, with a moderate level of evidence supporting the efficacy of adapted interventions 4
Treatment may require longer duration than standard protocols given developmental factors, with a low level of evidence supporting the importance of extended treatment duration [[not included due to lack of citation]]
Brief symptom exacerbation may occur during trauma processing, but this typically resolves by end of treatment, with a low level of evidence supporting the importance of monitoring for symptom exacerbation [[not included due to lack of citation]]